New piece up on the blog focuses specifically on insurance wholesaling. Specifically breaking down wholesaling to the classic wholesaler component and then also touching on some of the MGA/MGU business that exists. DMs open as always.
Mentioned:
$BWIN $TFC $RYAN
Enjoy!
@owl_poster
They're literally just hippies that studied geology, found out they loved money and could look at rocks and draw maps. They got hired back in the 70s/80s and are gods.
But they're just really talented petroleum geo's
There is a secret war occurring. The most important battle of our time and the belligerents are:
$LMND Bulls vs People That Know How To Read Insurance 10K’s
Godspeed
New piece is out on CHAPTERS Group AG - $CHG.DE.
This piece is a primer on the company, a serial acquirer for small and mid-sized enterprises located in Europe.
Next up will be a financials dive and setting the stage for an update in October following their interim report. I
This is… a positive development for the US market for $MOB.ST
Their competitors do not have this type arrangement. This is different (and better) than pre-authorization.
In this situation they’ll just shorten the prescription supply and cover each Rx so long as the patient
Forgive me, but I'm actually really shocked by the willingness of some people on here to just blanketly accuse someone of running a pump and dump without having done the work on the name.
I don't want to harp on the fungus as I have other names I focus on, but I don't understand
Some of the people critiquing MOB-015 potential for coverage in the USA:
It’s not like Jublia doesn’t make money in the US even despite its coverage challenges. If MOB-015 has the same coverage issues as Jublia, it means the current value of the co is still attractive.
Jublia
If I was creating a hedge fund today, these are the only four stocks I would buy:
- $SOFI
- $HIMS
- $AMZN
- $GOOG
Rest of my time would be spent by writing cool memos to clients.
My piece on pharmacy pricing, drug tier classification, how (health) insurers view risk, and how insurers might treat a new drug will be coming out this weekend.
I have other pieces planned that all relate to this, but I would love to hear requests for something specific as well
Yesterday I had a moment of pure clarity. I have a family that loves me, a life worth living, friends that support me, and a career that I enjoy.
There’s really nothing else that actually matters than the relationships we hold close.
I’m a lucky man and I hope you all are too.
“Go find your Charlie. And do it now.”
That was the gist of Warren’s answer to Andrew’s question, “if you had one more day with Charlie, what would you do with him?“
After a long, beautiful answer, Buffett brought it home with this banger.
New post is up with no paywall.
Discusses the role of wholesalers in the drug supply chain as well as the pricing dynamics between manufacturers, wholesalers, and pharmacies. Also provided insight into how that pricing dynamic impacts the end consumer and the insurer/PBM.
Hope
Think I'll start writing a bit more on the medical stop-loss industry and how these stop-loss insurers work within the healthcare landscape. Something not discussed as frequently, but a major portion of the US healthcare finance landscape.
New piece coming on Saturday. Will be how the PBMs view formulary placement, prior authorization, tier designations, and continuing further detail on the first piece.
Sorry for the hiatus, back to regularly scheduled programming. I think you’ll enjoy the next one.
This makes sense, for example: how many people selected at random have heard of $CPRT $LIN $PLD
All three are SP500 components.
Companies are known within their industry broadly speaking, but everyone in insurance or knows Marsh. It doesn’t mean they’re *better* however.
@ccmembersonly
Seller are the most delusional people in the market right now.
Just saw a home in a dogwater part of the northeast for >800k with a $16k tax bill.
It is approximately 2 hours from just about anything and hasn't been renovated since at least the 80s.
The really upsetting part about this storm is that even though the "worst case scenario" is likely avoided, wherever this hits will be devastated.
Hoping everyone on the West Coast stays safe.
My piece on pharmacy pricing, drug tier classification, how (health) insurers view risk, and how insurers might treat a new drug will be coming out this weekend.
I have other pieces planned that all relate to this, but I would love to hear requests for something specific as well
Anyone investing in insurance businesses:
Schiff's Insurance Observer just made free the entire archive - .
It's a treasure trove of great information.
@ChanisLament
Most people just have no clue what they’re talking about when it comes to us health insurance. They can barely understand their own deductible and coinsurance let alone the inner workings of drug placement on a formulary.
@ChrisOlin
@PedroLamento
@Divergent7651
I believe it will be far harder than she may expect, but in general she’s not commenting on the USA much until P3 given my own conversations with her, so I won’t pass judgement on this until we see further commentary on the overall strategy of the USA.
New post on the blog, very brief. Free for everyone. Breakdown of the platform companies that currently exist and then some redundant information from the previous post on the new platforms.
Interim report in October!
I should note, there’s other possible explanations for per completed treatment cycle, but this phrase is not indicative of coverage issues like pre-auth.
$CHG.DE September 5th, 2024
CHAPTERS Group officially owns 100% of their VMS-software platform Ookam Software GmbH. Previously, CHAPTERS owned 80% of Ookam.
Ookam operates 23 companies out of Germany, Austria, Czech Republic, and Slovakia.
@ChanisLament
Who would have thought a novel treatment better than current options wasn’t just a play on the current customer base, but on new customers that had been waiting for a better treatment option.
Does anyone have thoughts on $MRX or $ABXX?
MRX growth seems fairly compelling. Lot of interest income so far. Who would be the best person to speak with on here about either?
@ChanisLament
People don’t realize for companies (in general) you can’t just look at a multiple and go “hur dur” this is cheap.
Companies aren’t just shares trading on an exchange. They are businesses, with counterparties. One needs to understand those counterparties.
New post is up about a company that has performed well for me YTD, The Baldwin Group $BWIN.
A sector that I know well and a business compounding revenues double digits year over year. None of this is investment advice.
Please feel free to DM.
@AlvinZh2003
Don’t you think if it was a said pump and dump they would be exceedingly promotional of a stock into a warrant event that hits cash onto the balance sheet depending on the VWAP going into June?
You have no idea what you’re saying.
Since this post I have doubled my position size and the stock is +25% (approximately). I will have a brief note on the 'stack before the August 6th earnings with some updates I think are positive.
I know it's tired phrase, but I really don't care where the stock trades in the
New post is up about a company that has performed well for me YTD, The Baldwin Group $BWIN.
A sector that I know well and a business compounding revenues double digits year over year. None of this is investment advice.
Please feel free to DM.
It is becoming really difficult to not try and take advantage of the USDJPY exchange rate and buy a little cottage or something by the ocean. I like Japan and the surfing is great too.
Putting out a piece in the coming weeks about a name I've been long for a bit now.
Great sector, acquirer, and management. A growth name in a wonderful business that I think is poised to continue compounding.
Will be the first post that mentions a single stock name and I hope
@EquityBrian
$bwin
Highly acquisitive, earn outs from previous m&a spree rolling off, delevering even with earn out obligations, solid operator and incredible MGA/MGU biz
Short term- Once the brunt of these earn outs are complete the fcf profile of the biz materially improved as these earn
Family situation has arisen unfortunately - not the best start to Memorial Day weekend.
The piece will be out this coming week - there will be no paywall due to the delay.
New piece coming on Saturday. Will be how the PBMs view formulary placement, prior authorization, tier designations, and continuing further detail on the first piece.
Sorry for the hiatus, back to regularly scheduled programming. I think you’ll enjoy the next one.
@mhp_guy
"But that $2,000 line item effectively carries a potential "cost of risk" to the insurer of $60."
I need you to never speak about insurance ever again if you are going to say stuff like this. This is not how that works at all.
I am trying to be charitable so I will just say that:
if your concept to fix home insurance uses Obamacare/ACA as the foundation then you are too policy/academically focused and probably don’t understand how these systems work in a *real* capacity
This is an awful idea
🚨New Paper🚨 Happy to share Obamacare For Homeowners Insurance: Fixing America's Broken Insurance Markets In A Time Of Climate Change, f'coming in
@HarvardELR
, it argues the ACA offers a template for fixing insurance markets roiled by climate change. 1/12
@DakotasTwits
There was a great tweet about some European guy asking “with those sharp edges how did it pass pedestrian safety testing!?”
And he soon learned that we do not have such a thing.
I've mentioned this before, while the capital raises definitely give people cause for pause, they are not being punished by the market currently and are attracting phenomenal people as investors.
It's a unique position to be able to raise nearly 1/5 of the MC and then provide
Seen a bit of $ROOT posting so thought I'd maybe give my thoughts. It's very possible that it's a compelling long from here, but the beauty of $ROOT was the re-rate and the amount of work to get long this name has grown materially.
Buying a short tail insurer with a single line
@CorneliaLake
SOC has done everything right and followed the difficult CA process to a T. The consent decree has been agreed to by all relevant Parties (especially federal agencies)and takes precedent over any random state commission. The CCC and SLC know this and are just being true to
Seen a bit of $ROOT posting so thought I'd maybe give my thoughts. It's very possible that it's a compelling long from here, but the beauty of $ROOT was the re-rate and the amount of work to get long this name has grown materially.
Buying a short tail insurer with a single line
@PythiaR
I’ll add - Jublia at $100m and it’s not exactly fully covered by insurance easily. So the bear thesis that MOB-015 in the USA won’t be meaningful due to potential step therapy or bad formulary placement is dead on arrival.
Plus it’s a better product.
Going to be writing up another insurance long on the 'stack in the coming weeks.
It's a really interesting one with some a really unique component to it's ability to drive RoE. Good underwriters and sub <$10b MC.
A bit different than $BWIN. Soon!
Does anyone have a securities lawyer they can recommend? Ideally one that has been on the defense.
It seems I have found myself in quite the pickle. ty
@Longterms1
You clearly have no idea what you are talking about. This is extremely common. The pharmaceutical distribution system is built on discounts between parties and then discounts at the end consumer.
Happy to DM with you but if you don’t realize how common discounts are in pharmacy
I enjoy this topic honestly, mainly because two things can be true:
1. Working at a mega corp doesn’t make you better
2. Working at a mega corp *can* absolutely “pays you in brand name (brand within industry)
Both are true!
@Jaro_rogue
What you’re describing is called step therapy and it is too soon to be making declarative statements as to whether insurance co’s will require step therapy.
It’s entirely possible, but the existence of a Jublia generic isn’t a guarantee they’ll require step therapy. It’ll
Tiny rant:
In Germany/Belgium (and I am assuming other EU countries) a single transaction triggers VAT registration on Stripe.
Stripe makes it pretty easy, but I can completely see why people would geofence their services to not deal with this. I love Europe, but for example,
@shakoistsLog
I need to find the papers, but there’s great papers written about the type of mercury that are in fish not being as bio reactive as the mercury you typically think of when you think of mercury poisoning. I’ll try and find it and post it.
You can be as fast as you want, many instant quote solutions out there, but speed, while nice, isn’t the key issue if the rest of the market takes two weeks. Especially when you want to see the market for your risk.
That insurer is just saying the price first. Your buying
$PLTR CTO
@ssankar
🔮🤯
“One of our customers, a very large US insurance company… we’ve automated all of insurance underwriting. A process that used to take 2 weeks, can now be done in 3 hours”‼️
“If all of your competitors take 2 weeks to price risk, and you take 3 hours,
Data Center sectors, along with market leaders.
Are there any good SMB Data Center thesis ideas for Searchers, entrepreneurs, or independent sponsors here? Any thoughts?
What is your:
Best equity play currently? (L/S)
Best equity play in the past? (L/S)
What is a theme you think plays out in the coming years?
Want to hear from you all.
Interview with
@smallcapdisc
is now available for free on YouTube. I made a few mistakes in this video, but I wasn't exactly reading off a script.
Thanks for the opportunity
@PaulAndreola
&
@veritasvatillum